Indicated for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.1

Stay up to date with all the latest news at Daxocox®

Animalcare leads the conversation on osteoarthritis breakthrough pain with free CPD event

Animalcare is raising awareness of the need to avoid osteoarthritis breakthrough pain, starting with a free virtual CPD event led by RCVS & EBVS European Veterinary Specialist in Anaesthesia & Analgesia, Matt Gurney. The webinar is the first of several communication events that will focus attention on patients owned by the estimated 80% of owners who feel that their pets with canine osteoarthritis (OA) may be suffering from off-days that can be associated with breakthrough pain

Animalcare launches Daxocox®, the first and only weekly oral NSAID

Animalcare is excited to launch Daxocox® (enflicoxib, a selective COX-2 inhibitor), the first and only weekly oral NSAID. Daxocox® not only achieves significant improvement of clinical signs associated with the pain of osteoarthritis (OA) in dogs,1,2 but also helps reduce the risk of breakthrough pain.